BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 17549375)

  • 21. Expression of tyrosine kinase receptors in malignant midgut carcinoid tumors.
    Welin S; Fjällskog ML; Saras J; Eriksson B; Janson ET
    Neuroendocrinology; 2006; 84(1):42-8. PubMed ID: 17047316
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evidence for PDGFRA, PDGFRB and KIT deregulation in an NSCLC patient.
    Negri T; Casieri P; Miselli F; Orsenigo M; Piacenza C; Stacchiotti S; Bidoli P; Casali PG; Pierotti MA; Tamborini E; Pilotti S
    Br J Cancer; 2007 Jan; 96(1):180-1. PubMed ID: 17213828
    [No Abstract]   [Full Text] [Related]  

  • 23. A phase 2 trial of imatinib mesylate in patients with recurrent nonresectable chondrosarcomas expressing platelet-derived growth factor receptor-α or -β: An Italian Sarcoma Group study.
    Grignani G; Palmerini E; Stacchiotti S; Boglione A; Ferraresi V; Frustaci S; Comandone A; Casali PG; Ferrari S; Aglietta M
    Cancer; 2011 Feb; 117(4):826-31. PubMed ID: 20925044
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Potential role of imatinib mesylate (Gleevec, STI-571) in the treatment of vestibular schwannoma.
    Altuna X; Lopez JP; Yu MA; Arandazi MJ; Harris JP; Wang-Rodriguez J; An Y; Dobrow R; Doherty JK; Ongkeko WM
    Otol Neurotol; 2011 Jan; 32(1):163-70. PubMed ID: 21157293
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Response of a KIT-positive extra-abdominal fibromatosis to imatinib mesylate and KIT genetic analysis.
    Gonçalves A; Monges G; Yang Y; Palmerini F; Dubreuil P; Noguchi T; Jacquemier J; Di Stefano D; Delpero JR; Sobol H; Bertucci F
    J Natl Cancer Inst; 2006 Apr; 98(8):562-3. PubMed ID: 16622127
    [No Abstract]   [Full Text] [Related]  

  • 26. Analysis of mutation and expression of c-kit and PDGFR-alpha gene in gastrointestinal stromal tumor.
    Zheng S; Chen LR; Wang HJ; Chen SZ
    Hepatogastroenterology; 2007 Dec; 54(80):2285-90. PubMed ID: 18265649
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel treatment of ovarian cancer cell lines with Imatinib mesylate combined with Paclitaxel and Carboplatin leads to receptor-mediated antiproliferative effects.
    Mundhenke C; Weigel MT; Sturner KH; Roesel F; Meinhold-Heerlein I; Bauerschlag DO; Schem C; Hilpert F; Jonat W; Maass N
    J Cancer Res Clin Oncol; 2008 Dec; 134(12):1397-405. PubMed ID: 18465140
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunohistochemical and mutational analysis of PDGF and PDGFR in desmoid tumours: is there a role for tyrosine kinase inhibitors in c-kit-negative desmoid tumours?
    Liegl B; Leithner A; Bauernhofer T; Windhager R; Guelly C; Regauer S; Beham A
    Histopathology; 2006 Dec; 49(6):576-81. PubMed ID: 17163842
    [TBL] [Abstract][Full Text] [Related]  

  • 29. KIT-negative undifferentiated endometrial sarcoma with the amplified epidermal growth factor receptor gene showing a temporary response to imatinib mesylate.
    Mitsuhashi T; Nakayama M; Sakurai S; Fujimura M; Shimizu Y; Ban S; Ogawa F; Hirose T; Ishihara O; Shimizu M
    Ann Diagn Pathol; 2007 Feb; 11(1):49-54. PubMed ID: 17240308
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Imatinib mesylate in chordoma.
    Casali PG; Messina A; Stacchiotti S; Tamborini E; Crippa F; Gronchi A; Orlandi R; Ripamonti C; Spreafico C; Bertieri R; Bertulli R; Colecchia M; Fumagalli E; Greco A; Grosso F; Olmi P; Pierotti MA; Pilotti S
    Cancer; 2004 Nov; 101(9):2086-97. PubMed ID: 15372471
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expression and mutational analysis of tyrosine kinase receptors c-kit, PDGFRalpha, and PDGFRbeta in ovarian cancers.
    Wilczynski SP; Chen YY; Chen W; Howell SB; Shively JE; Alberts DS
    Hum Pathol; 2005 Mar; 36(3):242-9. PubMed ID: 15791568
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Activating mutations in receptor tyrosine kinases with relevance for treatment of gastrointestinal stromal tumors].
    Wardelmann E; Merkelbach-Bruse S; Büttner R; Schildhaus HU
    Verh Dtsch Ges Pathol; 2007; 91():165-8. PubMed ID: 18314611
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Brief report: activity of imatinib in a patient with platelet-derived-growth-factor receptor positive malignant solitary fibrous tumor of the pleura.
    De Pas T; Toffalorio F; Colombo P; Trifirò G; Pelosi G; Vigna PD; Manzotti M; Agostini M; de Braud F
    J Thorac Oncol; 2008 Aug; 3(8):938-41. PubMed ID: 18670317
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Response of histiocytoses to imatinib mesylate: fire to ashes.
    Janku F; Amin HM; Yang D; Garrido-Laguna I; Trent JC; Kurzrock R
    J Clin Oncol; 2010 Nov; 28(31):e633-6. PubMed ID: 20733125
    [No Abstract]   [Full Text] [Related]  

  • 35. Combination of imatinib and vinorelbine enhances cell growth inhibition in breast cancer cells via PDGFR beta signalling.
    Weigel MT; Meinhold-Heerlein I; Bauerschlag DO; Schem C; Bauer M; Jonat W; Maass N; Mundhenke C
    Cancer Lett; 2009 Jan; 273(1):70-9. PubMed ID: 18809244
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer.
    Modi S; Seidman AD; Dickler M; Moasser M; D'Andrea G; Moynahan ME; Menell J; Panageas KS; Tan LK; Norton L; Hudis CA
    Breast Cancer Res Treat; 2005 Mar; 90(2):157-63. PubMed ID: 15803362
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Imatinib and solid tumours].
    Arifi S; El Sayadi H; Dufresne A; Ray-Coquard I; Fayette J; Méeus P; Ranchère D; Decouvelaere AV; Alberti L; Tabone-Eglinger S; Blay JY; Cassier P
    Bull Cancer; 2008 Jan; 95(1):99-106. PubMed ID: 18230575
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Osteoblast-conditioned medium promotes proliferation and sensitizes breast cancer cells to imatinib treatment.
    Brama M; Basciani S; Cherubini S; Mariani S; Migliaccio S; Arizzi M; Rosano G; Spera G; Gnessi L
    Endocr Relat Cancer; 2007 Mar; 14(1):61-72. PubMed ID: 17395975
    [TBL] [Abstract][Full Text] [Related]  

  • 39. First case of an AIDS patient with systemic mast cell disease associated with FIP1-positive eosinophilia treated with imatinib mesylate therapy.
    Merante S; Chichino G; Boveri E; Gottardi E; Soverini S; Cilloni D; Martinelli G
    J Clin Oncol; 2006 Feb; 24(4):e6-7. PubMed ID: 16446324
    [No Abstract]   [Full Text] [Related]  

  • 40. Growth factor receptor expression in orbital lymphangioma: possible therapeutic implications.
    Esmaeli B; Prieto VG; Gonnering R; Hawes MJ; Diba R; Saadati HG; Shepler TR; Karcioglu Z
    Orbit; 2004 Dec; 23(4):263-9. PubMed ID: 15590529
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.